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Recently, considerable attention has focused
on a wide variety of endocrine disrupting
chemicals in the environment that have
estrogenic activity, variously referred to as
environmental estrogens, xenobiotic estro-
gens, or xenoestrogens. Bisphenol A and the
alkylphenols (nonylphenol and octylphe-
nol) have been reported to have estrogenic
activity (1-5). Bisphenol A is an essential
component of epoxy resins used in the lac-
quer lining of metal food cans (6), as a
component of polycarbonates (3), and in
dental sealants (7). Octylphenol and
nonylphenol are industrial additives used in
a wide variety of detergents and plastics;
these compounds are reported to be envi-
ronmentally persistent (5). Bisphenol A,
nonylphenol, and octylphenol are synthetic
chemicals that are not estrogenic by design,
but were only accidentally discovered to
have estrogenic activity. Many other syn-
thetic compounds have also been reported
to show estrogenic activity (8). Develop-
ment ofrapid, inexpensive in vitro assays to
accurately predict the estrogenic activity of
man-made chemicals in humans and ani-
mals is thus of considerable importance
with regard to public health and the
preservation ofwildlife.
A number of in vitro assays have been
developed to characterize the activity of
estrogens, and many ofthese assays are now
in use to characterize the estrogenic activity
of xenoestrogens in the environment.
MCF-7 cell proliferation (9-11) or the E-
SCREEN (8,12) is one of the most sensi-
tive in vitro bioassays to measure estrogenic
activity; concentrations in medium as low
as 0.2 pM of 170-estradiol (0.05 pg/ml;
0.05 parts per trillion) can produce asignif-
icant increase in proliferation relative to
baseline (13). However, while the MCF-7
cell proliferation assay is excellent for
detecting the estrogenic activity of known
compounds or the presence of estrogenic
activity in mixtures of unknown chemical
composition, the cell proliferation assay
may not be the most predictive in vitro
assay for determining overall bioactivity of
specific xenoestrogens in animals. One
major reason is that the MCF-7 cell prolif-
eration assay is conducted in tissue culture
medium which contains only 5-10% serum
and does not address how xenoestrogens are
influenced by pharmacokinetics and by
components of serum that dramatically
influence the activity of steroidal estrogens,
which are primarily bound to serum pro-
teins in circulation (14).
The bioactivity ofa xenoestrogen in the
animal is affected byfour keyfactors:
* Absorption and metabolism relative to the
route ofexposure
* Partitioning between aqueous and lipid
compartments
* Effective concentration determined byhow
it is carried in circulation
* Intrinsic estrogenic activityofthe molecule
through its binding to and activation of
estrogen receptors.
Currently, most in vitro assays measure pri-
marily the fourth factor, intrinsic estrogenic
activity of xenoestrogens. We have under-
taken to develop in vitro assays to assess the
additional factors, beginning with how
xenoestrogens are carried in blood.
To determine whether the effects of
serum on cell uptake can aid in estimating
the bioactivity of xenoestrogens in animals
and ultimately in humans, we developed
the relative binding affinity-serum modified
access (RBA-SMA) assay. In this assay, we
examine how serum modifies the access of
xenoestrogens to intracellular estrogen
receptors within intact MCF-7 human
breast cancer cells by comparing the relative
binding affinity (RBA; relative to estradiol)
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ofa xenoestrogen in serum-free medium to
its RBA measured in 100% serum. Our in
vitro assay takes into account the intrinsic
activity of xenoestrogens (measured as
affinity for the estrogen receptor), as do
other in vitro assays. However, the RBA-
SMA assay includes the effects of how
xenoestrogens are carried in blood and the
partitioning ofxenoestrogens in serum and
cell lipids by using 100% serum and live
human cells rather than cell-free systems.
We examined the effect of serum on
the estrogenic activity ofthe xenoestrogens
bisphenol A, octylphenol, and nonylphenol
in the RBA-SMA assay. The estrogenic
activities of these compounds have been
examined in other in vitro assays (3,5),
with bisphenol A reported to be approxi-
mately 10-fold less estrogenic than
octylphenol (15). However, in the RBA-
SMA assay, bisphenol A was determined to
be considerably more estrogenic than
octylphenol, therefore we predicted that
the relative potencies in vivoofbisphenol A
and octylphenol would differ from those
found by current in vitro methods. We
administered bisphenol A and octylphenol
to pregnant mice and examined whether
this led to a permanent increase in prostate
weight in the male offspring at 6 months of
age, since we have previously described that
this is a sensitive bioassay for detecting a
very small increase in serum estradiol in
mouse fetuses (16,17). Our prediction
from the RBA-SMA assay that bisphenol A
would alter fetal development in mice at a
significantly lower dose than octylphenol
was confirmed when the same doses of
these compounds were fed to pregnant
mice to compare their bioactivity in terms
of effects on prostate enlargement in male
offspring. In addition to demonstrating the
utility ofthe RBA-SMA assay, a significant
finding bearing on environmental xenoe-
strogens is that the doses of bisphenol A
that affected fetal development were within
the current range of human exposure to
bisphenol A (6,7).
Materials and Methods
Materials. Minimum essential medium
(MEM with nonessential amino acids,
powdered), HEPES, bovine insulin, calf
thymus DNA type I, Hoechst dye 33258,
streptomycin sulfate, penicillin-G, 17f3-
estradiol (MW 272.4), EDTA, Hanks' bal-
anced salt solution (HBSS), bovine serum
albumin (BSA), and human male serum
were obtained from Sigma Chemical
Company (St. Louis, MO); all were "cell
culture tested" when available. Bovine calf
serum, phenol red (sodium salt), and
lyophilized trypsin were obtained from
Gibco BRL (Grand Island, NY). Bisphenol
A (research grade, MW 228.3) was
obtained from Aldrich Chemical Company
(Milwaukee, WI). 4-Octylphenol (MW
208.3) technical grade and 4-nonylphenol
(MW 222.35) technical grade were pur-
chased from Chem Service (West Chester,
Pennsylvania). 1,2,6,7[3H]estradiol, 104
Ci/mol, was purchased from DuPont New
England Nuclear (Boston, MA). All other
chemicals were reagent grade.
Cell culture. MCF-7 cells were
obtained from V. Craig Jordan, University
ofWisconsin-Madison. MCF-7 cells were
maintained in MEM with nonessential
amino acids, 10 pg/ml phenol red, 10 mM
HEPES, 6 ng/ml insulin, 100 units/ml
penicillin, 100 pg/ml streptomycin, and
5% charcoal-stripped calf serum (mainte-
nance medium) (18,19). Because the
responsiveness of MCF-7 cells that are
maintained continuously in stripped calf
serum can drift (20), cells were propagated
in stripped calf serum for approximately 1
year and then replaced with cells derived
from our primary source-MCF-7 cells
which had been maintained in whole
serum before storage in liquid N2.
Relative binding affinity assay. Relative
binding affinity assays were performed in
24-well tissue culture plates. MCF-7 cells
were seeded at approximately 100,000 cells
per well in estrogen-free medium (mainte-
nance medium without phenol red), and
the cells were cultured for 3 days, with fresh
medium added 1 day prior to the assay.
Adult human serum was thawed, the pH
was adjusted to 7.0, and the serum was fil-
tered through a series offilters from 0.8 to
0.2 pm, including a Gelman G20 glass fiber
prefilter (1.0 pm; Gelman Sciences, Ann
Arbor, MI), to remove lipid precipitate.
RBA analyses were conducted as com-
petition assays against 1 nM [3H]estradiol
in serum-free medium (SFM; MEM with
nonessential amino acids plus 10 mM
HEPES) or against 10 nM [3H]estradiol in
100% serum. The concentration range of
unlabeled test compounds was 10-7_10-4 M
in both SFM and 100% serum. The concen-
tration range ofnonradioactive estradiol (the
reference competition) was 10-1-10-7 M in
SFM, and 10-9_10-6 M in 100% serum.
Test solutions were prepared in glass with
1% solvent ethanol present and then allowed
to equilibrate with serum components for 1
hr at 37°C under 5% CO2 priorto the assay.
Cells were incubated with 0.5 ml/test
media/well at 37°C and 5% CO2 for 18 hr.
At the end of the incubation, the medium
was removed and the wells were washed
three times with 1 ml HBSS that contained
bovine serum albumin (BSA) at 2 mg/ml,
oncewith 2 ml HBSS alone, andfinallywith
3 ml HBSS. The washed cells were dissolved
(21) in 1 ml 10 mM EDTA, pH 12.4
(25°C, 15 min), neutralized (final pH = 7.2)
with 0.1 ml 0.77 M KH2PO4, and sonicat-
ed. Aliquots were then taken for scintillation
counting or measurement ofDNA.
Relative binding affinity calculation.
For each xenoestrogen and for nonradioac-
tive reference estradiol, the concentration
required to inhibit 50% (IC50) ofspecifical-
ly bound [3H]estradiol was determined. To
calculate the RBA, the IC50 for unlabeled
reference estradiol was divided by the IC50
for each xenoestrogen, and this number was
expressed as a percent. This same calcula-
tion was performed on data from the assay
using 100% serum as the medium. This
allowed us to determine whether serum
changed the RBAofthexenoestrogen.
Relativebindingaffinity-serum modified
access calculations. The RBA-SMA assay
determines the effect ofserum on the access
of xenoestrogens to intracellular receptors
within intact MCF-7 human breast cancer
cells. The RBA value (relative to estradiol)
obtained for the xenoestrogen in 100%
human serum is divided by the RBA
obtained in serum-free medium, and we
termed this ratio the serum modified access
(SMA) value. When an SMA value = 1 for
binding to intracellular estrogen receptors,
the xenoestrogen exhibited the same binding
affinity relative to estradiol in the presence or
absence ofserum. That is, the xenoestrogen
exhibited the same change in potency as did
estradiol in the presence ofserum. However,
an SMA value >1 indicates that the xenoe-
strogen has greater access to intracellular
estrogen receptors when reaching the cells
from serum; conversely, an SMA <1 indi-
cates that the presence ofserum reduced the
access of the xenoestrogen to intracellular
estrogen receptors, again relative to estradiol.
DNA assay. DNAwas measured fluoro-
metrically in an aliquot of the sonicate
using Hoechst dye 33258 according to the
method of Labarca and Paigen (22). Calf
thymus DNA was used as the standard
after calibration by absorbance at 254 nm,
assuming 20 absorbance units for 1 mg
DNAper ml.
Animals, housing and mating. CF-1
mice (Mus musculusdomesticus) were initial-
ly obtained in 1979 from Charles River
Laboratories (Wilmington, MA) and were
maintained on Purina Laboratory Chow
(Richmond, IN) (5001) as an outbred
colony in a closed facility since that time.
Animals were housed in standard (11.5 x
7.5 x 5 in) polypropylene mouse cages on
corn cob bedding. Rooms were maintained
at 25°C ± 20 under a 12:12 light:dark (L:D)
cycle, with lights on at 12 P.M. (so that
timed mating could occur at the end ofthe
darkphase, i.e., in mid- to late morning).
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The males exposed to chemicals during
fetal life were produced by mating adult
virgin female mice. Females were time
mated by being placed daily with a stud
male for 4 hr at the end of the dark phase
of the L:D cycle. Mating was verified by
the presence of a seminal plug. Females
were allowed to deliver normally on gesta-
tion day 19. Pups were weaned at 23 days
of age, and male littermates were housed
three per cage.
One male per litter was randomly select-
ed for use in this study to control for litter
effects (the remaining animals were used in
other studies), and this selected male was
individually housed for 1 month. When
CF-I males are housed in groups, a nonlin-
ear dominance hierarchy is often observed in
which there is one dominant male and the
remaining males are subordinate (23); dom-
inance status has marked effects on repro-
ductive organs in CF-1 male mice.
However, individual housing for 1 month
eliminates the prior effects ofsubordination
(F. vom Saal, unpublished observation).
Administration ofxenoestrogens to
pregnantfemales. Two different doses of
bisphenol A and octylphenol were fed to
pregnant mice (seven per group), at 2 and
20 jig/kg bodyweight (bw). Chemicals were
dissolved in tocopherol-stripped corn oil
(Cat# 901415; ICN, Aurora, OH), and 30
i ofoil containing different concentrations
of each chemical was fed to pregnant mice
one time per day at 10 A.M. from gestation
day (GD) 11 to GD 17. This time in preg-
nancy was chosen to expose the fetuses to
the xenoestrogens throughout the prenatal
period of sexual differentiation and during
the initial differentiation of the prostate
(24). The last dose was administered on GD
17 to reduce the possibility of interfering
with normal parturition; interference occurs
with high doses ofestrogenic chemicals (25).
Bisphenol A, octylphenol, and control corn
oil alone were fed with a micropipettor to
the dams, who readily accept the oil without
the potential stress of gavage. There were
two control groups: one group (unhandled
controls, n = 5) remained unhandled
throughout pregnancy and the other group
(vehicle controls, n = 6) was fed 30 p1 of
corn oil from GD 11 to GD 17.
Prostate collection. Body weight was
determined for the randomly selected indi-
vidually housed males at 6 months of age
and then the males were killed by CO2
asphyxiation and cervical dislocation. The
entire reproductive tract was removed. The
entire prostate, including the ventral and
dorsolateral lobes (26), was stripped off of
the urethra, and prostate weight was deter-
mined using a Mettler (Hightstown, NJ)
AE-163 analytical balance.
Statistical analysis. Prostate weight for
males from the different prenatal treatment
groups was compared by analysis ofcovari-
ance (ANCOVA), with body weight used as
the covariate. ANCOVA provides an adjust-
ed organ weight after correcting all groups to
a common body weight. If the ANCOVA
showed that bodyweightdid not account for
a significant component of the variance in
organ weight, the data were then reanalyzed
using analysis ofvariance (ANOVA), and the
group means were presented without being
adjusted for body weight. Planned compar-
isons were made using the LS means test.
The confidence level for determining statisti-
cal significance was 5%. The Statistical
Analysis System (SAS, Cary, NC) on the
University of Missouri mainframe IBM
computer (White Plains, NY) was used for
these analyses.
Results
Relative binding affinity-serum modified
access assay. In the RBA-SMA assay, unla-
beled xenoestrogens competed with
[3H]estradiol for binding to estrogen recep-
tors in intact MCF-7 cells. Competition of
unlabeled xenoestrogens, which are full
estrogen agonists, is proportional to their
affinity for the estrogen receptor and thus
their estrogenic activity. The assay was first
conducted in serum-free medium and an
RBA was calculated. The same assay was
then conducted in 100% serum, and the
RBA obtained was compared to the RBA
measured in serum-free medium to deter-
mine how serum modified the access ofthe
xenoestrogen to intracellular estrogen
receptors. Xenoestrogen competition pro-
files from a single experiment conducted in
serum-free medium and in 100% adult
serum are presented in Figure 1. In serum-
free medium (Fig. IA), octylphenol exhib-
ited an RBA that was approximately 10-
fold greater than the RBA ofbisphenol A.
However, when the competing compounds
were tested in 100% serum, the relation-
ship of the competition profiles was
reversed and the RBA of bisphenol A was
greater than that ofoctylphenol (Fig. IB).
A summary ofthree independent RBA-
SMA assays of bisphenol A, nonylphenol,
and octylphenol is presented in Table 1.
The table includes the RBA measured in
serum-free medium, the RBA measured in
100% adult serum, and the calculated
SMA. The RBA of bisphenol A in serum
was 1.7-fold higher than that measured in
serum-free medium (Table 1, SMA = 1.7
for bisphenol A), indicating that its biolog-
ical impact relative to estradiol would be
underestimated by this factor in serum-free
assays. In contrast, nonylphenol and
octylphenol both showed an SMA <1
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Figure 1. Relative binding affinity-serum modified
access (RBA-SMA) assay. Unlabeled reference
estradiol, octylphenol, or bisphenol A competed
with (A) 1 nM [3H]estradiol in serum-free media or
(B) 10 nM [3H]estradiol in 100% adult male serum.
Specific binding averaged 3.8 fmol/pg DNA in SFM
and 1.7 fmol/pg DNA in serum. Nonspecific binding
ranged from 11 to 19% of total binding in SFM and
29to 49% oftotal binding in serum.
(Table 1; SMA = 0.2 and 0.045, respective-
ly), indicating that serum decreased their
relative access to estrogen receptors by 5-
fold and 22-fold, respectively. Hence, their
activity relative to estradiol would be over-
estimated in serum-free assays. Clearly, the
access of these three xenoestrogens was
affected by the presence ofserum, and the
effect of serum on octylphenol and
nonylphenol was in the opposite direction
to its effects on bisphenol A. Because they
showed the greatest difference in serum-
modified access, bisphenol A and octylphe-
nol were chosen to feed to pregnant mice
to test the predictability of the RBA-SMA
assay for bioactivity in the animal.
Thepredicted relative in vivo activity
ofbisphenol A and octylphenol in fetal
mouse serum basedon the RBA-SMA assay.
The results obtained for the effects ofserum
on the activity ofbisphenol A and octylphe-
nol were used to estimate what the relative
bioactivities would be in the animal, specifi-
cally in fetal mice where small increases in
estradiol during development result in per-
manent developmental changes in the
prostate (17) and increased prostate weight
in adulthood (16). Ideally, the effects of
serum-modified access on the estrogenic
activity of these compounds would have
been calculated directly from RBA values
determined using fetal mouse serum.
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Table 1. Relative binding affinity-serum modified access(RBA-SMA) assay
Compound No. of assays RBA in SFM (%) ± SE RBA in serum (%) ± SE SMA ± SE
Estradiol 3 100 100 1.00
Bisphenol A 3 0.0060 ± 0.0009 0.0100 ± 0.0012 1.70 ± 0.29
Nonylphenol 3 0.026 ± 0.0069 0.0039 ± 0.0011 0.20 ± 0.11
Octylphenol 3 0.072 ± 0.0152 0.0029 ± 0.0005 0.045 ± 0.013
Abbreviations: RBA, relative binding affinity; SFM, serum-free medium; SE, standard error; SMA, serum
modified access (RBA in serum RBA in serum-free medium).
RBA analysis was conducted in SFM and in 100% adult male serum. SMA values are the mean of three
independent RBA-SMA assays. Bisphenol A showed enhanced access from serum while octylphenol and
nonylphenol showed decreased access from serum relative to estradiol. Average concentration that
inhibited 50% (IC50)values in serum-free medium were 5.64 x 10-10 M, 8.57 x 10-6 M, 2.74 x 10-6 M, and 6.30
x 10-7 M for estradiol, bisphenol A, nonylphenol, and octylphenol, respectively. Corresponding values in
serum were 3.96 x 10-9 M, 3.94x 10-5 M, 1.11 x 10-4 M, and 1.45 x 10-4 M, respectively.
Table 2. Predicted serum modified access (SMA)a in fetal mouse serum estimated by extrapolation from
SMA in human serum
Estimated
Serum-free Adulthuman fetal mouse Predicted SMA
(100% free E2) (4%free E2) (0.2% free E2) infetal mouse
BisphenolA 1.0 1.7 (1.7 -1)x20b+ 1 = 15
Octylphenol 1.0 0.045 0.045 20b = 0.0022
Abbreviations:E2, 170-estradiol; RBA, relative binding affinity.
aSMA = RBA in serum - RBA in serum-free medium.
b4÷0.2% = 20-fold.
Table 3. Predicted estrogenic activitya calculated from the predicted serum modified access (SMA) for
bisphenol Aand octylphenol
Predicted SMA RBA in serum- Predicted Relative
in fetal mouse free medium bioactivityb activityc
Bisphenol A 15 x 0.006% = 0.09% 563
Octylphenol 0.0022 x 0.072% = 0.00016% 1
RBA, relative binding affinity.
aPredicted SMA x RBA in serum-free medium = predicted RBA in fetal mouse serum.
bPredicted estrongenic activity in fetal mouse serum.
cPredicted bioactivity ofbisphenolANoctylphenol.
However, the large volume of fetal mouse
serum required for these measurements was
not available. In the absence of fetal serum
data, we extrapolated the SMA calculations
obtained in adult male serum to what might
be expected in fetal mouse serum by assum-
ing that the effects on the SMA would be
roughly proportional to the free fraction of
estradiol in the two sera.
The free fraction of estradiol in fetal
mouse serum during the time ofsexual dif-
ferentiation and initiation ofprostate devel-
opment is 0.2% (vom Saal et al., unpub-
lished data), which is similar to that previ-
ously reported in fetal rats (22). The 0.2%
free fraction ofestradiol in fetal mice is 20-
fold lower than the 4% free estradiol in the
adult male serum (28) that we used to mea-
sure the SMA above (4% - 0.2% = 20-
fold). We have observed a linear relation-
ship between the percent offree estradiol in
serum and the SMA when the RBA assay
was conducted with serial dilutions ofadult
serum. Therefore, we estimated that the
effects offetal mouse serum on the access of
xenoestrogens to estrogen receptors would
be approximately 20-fold greater than the
effects we measured in adult serum. The
deviations in the SMAfrom thevalue of 1.0
in adult serum were thus altered by a factor
of20 for both bisphenol A and octylphenol
in order to predict the SMA in fetal serum;
this calculation for conversion of the SMA
in adult serum (4% free estradiol) to the
SMA in fetal serum (0.2% free estradiol) is
shown in Table 2. The calculation step
(multiplication or division) involving the
correction factor (20-fold) depends on
whether the SMA value showed enhance-
ment (SMA >1) or inhibition (SMA <1) of
cell uptake. If the SMA >1, the degree of
enhancement of cell uptake is determined
by multiplying the SMA in adult serum by
the correction factor; hence, the enhance-
ment will be greater relative to estradiol. If
the SMA <1, the assumption is that in fetal
serum the cell uptake would be even less
than estradiol, and the SMA value is divid-
ed by the correction factor.
The SMA values for bisphenol A and
octylphenol predicted for fetal mouse
serum were then applied to adjust the
activity of the compounds measured in
serum-free medium to the bioactivity pre-
dicted in fetal mouse serum (Table 3). The
predicted bioactivity in fetal mouse serum
was calculated by multiplying the RBA
measured in serum-free medium by the
predicted SMA in fetal serum. These calcu-
lations predicted that in the presence of
fetal mouse serum (all other factors being
equal), bisphenol A would exhibit over
500-fold greater bioactivity than would
octylphenol in mouse fetuses, despite the
higher intrinsic estrogenic activity of
octylphenol that was observed before tak-
ing serum into account.
Effect ofexposure to bisphenolA and
octylphenol duringfetal life on adult
prostate weight in mice. We administered 2
and 20 jig/kg bisphenol A per day to preg-
nant mice; these doses are within the range
ofdaily human exposure (6,2). Our expec-
tation was that ifthe RBA-SMA assay cor-
rectly predicted estrogenic bioactivity in the
animal, then the 20 pg/kg dose ofbisphenol
A would result in enlargement of the
prostate in adult male offspring, similar to
our earlier finding that a small increase in
fetal serum estradiol permanently increased
prostate size in mice (16). In contrast, we
expected that the 2 pg/kg dose ofbisphenol
A might be too low to produce a detectable
change in prostate weight. We predicted
that feeding the same two doses of
octylphenol would not result in a signifi-
cant change in the prostate of male off-
spring because the RBA-SMA assay predict-
ed that octylphenol would be 500-fold less
active than bisphenol A (Table 2). This was
a preliminary experiment to examine the
predicted relative activities of bisphenol A
and octylphenol from the RBA-SMA assay.
There were two control groups: one
group (unhandled controls) remained
unhandled throughout pregnancy, and the
other group (vehicle controls) was fed 30 p1
of corn oil from GD 11 to GD 17. There
were no significant differences between the
oil-fed controls and the unhandled controls
in body weight or prostate weight, indicat-
ing that the method of administration did
not affect these parameters. Therefore, these
two groups were pooled and treated as one
control group for the following analyses.
ANCOVA showed that prostate weight
varied significantly as a function ofprenatal
treatment [F (4,27) = 10.0; p<0.001], while
body weight did not account for a signifi-
cant component ofthe variance in prostate
weight. Based on these findings we reana-
lyzed prostate weight using ANOVA and
again there was a significant effect ofprena-
tal treatment on prostate weight (p<0.01).
Both ANOVA and ANCOVA yielded
identical results with regard to group means
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Figure 2. Prostate weight in adult male mice (6
months old) exposed as fetuses to bisphenol A or
octylphenol. Mothers were fed 2 or 20 pg/kg body
weight/day bisphenol A or octylphenol from days 11
to 17 of pregnancy. Error bars are the standard
error; n=7for bisphenol A and octylphenol, and n=
11 forunexposed controls.
*p<0.01.
and group differences in prostate weight,
and prostate weight in Figure 2 is thus pre-
sented uncorrected forbodyweight.
Prostates collected from 6-month-old
maleswhose mothers had been fedbisphenol
Aat either 2 or 20 /kg bw/daywere signif-
icantly heavier than prostates from control
males (Fig. 2), weighing 30% and 35% more
than control prostates at the low and high
dose ofbisphenol A, respectively. However,
prostates from males exposed prenatally to
either the 2 or 20 pg dose of octylphenol
were not significantly different from the
prostates from control animals (Fig. 2).
Based on the doses that we administered in
this preliminary experiment, bisphenol A
appeared to be at least 100-fold more estro-
genic than octylphenol, which is consistent
with the prediction derived from the calcula-
tions from the RBA-SMA assay above. An
interesting finding was that the coefficient of
variation (CV) forprostateweight ofanimals
exposed to the highest dose (20 pg) ofboth
bisphenol A and octylphenol was three-fold
greater than the CV for the animals exposed
to the lower doses (2 pg), suggesting greater
variance in response to the higher of these
two lowdoses.
Body weight differed significantly as a
function of prenatal treatment group [F
(4,27) = 3.8; p<0.05). Males exposed to
both the low dose ofbisphenol A [34.6 ±
1.12; n = 7; mean ± standard error (SE) and
octylphenol (33.4 ± 1.11, n = 7) were signif-
icantly lighter than control males (37.9 ±
0.83; n = 11), while exposure to the high
doses of both bisphenol A and octylphenol
(36.7 ± 1.12; n = 7 and 37.3 ± 0.73; n = 7,
respectively) did not influence bodyweight.
However, as described above, adjusting
prostate weight for body weight did not
alter the results with regard to group differ-
ences in prostate weight, since body weight
was not correlated with prostate weight
(Pearson's r(39) = 0.19;p = 0.25).
Discussion
In prior published assays ofestrogenic activ-
ity that have not taken the effects ofserum
into account, bisphenol A was reported to
have one-halfto one-tenth ofthe estrogenic
activity ofoctylphenol (3,5,15); when mea-
sured in serum-free medium in our RBA-
SMA assay, bisphenol A showed one-tenth
the activity ofoctylphenol and also exhibit-
ed a lower RBA than nonylphenol.
However, in the portion of the RBA-SMA
assay conducted in 100% adult human
male serum, bisphenol A showed a greater
relative estrogenic activity than either
octylphenol or nonylphenol. The results of
the RBA-SMA assay led to the prediction
that bisphenol A would be substantially
more estrogenic than octylphenol in the
mouse fetus. This was confirmed when
bisphenol A at maternal doses of2 and 20
pg/kg stimulated prostate enlargement in
male offspring, while octylphenol at the
same doses did not alter prostate weight.
The RBA-SMA assay therefore provided a
substantial improvement over existing in
vitro assays for predicting the bioactivity of
thesexenoestrogens in the animal.
The effects ofserum on the cell uptake
and binding to estrogen receptors ofbisphe-
nol A, nonylphenol, and octylphenol were
in opposite directions. The activity of
bisphenol A was slightly enhanced in serum
while the activity of nonylphenol and
octylphenol was dramatically decreased rela-
tive to estradiol. It is likely that there are
multiple mechanisms mediating both the
increased (SMA >1) and decreased (SMA
<1) activity of xenoestrogens observed in
serum relative to serum-free medium.
While estradiol is primarily bound to pro-
teins in serum, xenoestrogens that do not
bind to these proteins may escape this
mechanism, which limits the cell uptake of
natural estrogens. Several xenoestrogens
have been reported to show less binding to
serum proteins than estradiol (29-34). This
may increase their effective concentration
relative to estradiol and lead to increased
estrogenic activity of these compounds.
Conversely, xenoestrogens that showgreater
binding to serum proteins or greater lipid
partitioning may have a lower free fraction
than estradiol, thus decreasing their effec-
tive concentration in serum. Octylphenol
has been reported to show less binding to
human serum proteins [both sex hormone-
binding globulin (SHBG) and albumin]
than estradiol (34); however, in the RBA-
SMA assay, serum inhibited octylphenol
from binding to the estrogen receptor more
than estradiol. This suggests that factors
other than binding to serum proteins, such
as lipid partitioning (either serum or mam-
malian cell membrane), may play a role in
the activity ofsome xenoestrogens; the alkyl
chain present in octylphenol and nonylphe-
nol (but not bisphenol A) may be impor-
tant in this regard. However, at this time
the mechanism of decreased access of
xenoestrogens from serum is unknown and
will require furtherstudy.
Most xenoestrogens are not available in
radiolabeled form, so the effects ofserum on
their access to estrogen receptors could notbe
measured directly. Therefore, we used RBA
analysis to compare the access ofxenoestro-
gens with tritiated estradiol. The RBA-SMA
assay measured access ofxenoestrogens from
human serum into live human cells. Ideally,
the RBA-SMA assay should be conducted in
serum from the animal and lifestage atwhich
the estrogenic activity is in question. Because
the quantities offetal mouse serum required
for the RBA-SMA assay were not available,
we extrapolated the results from adult human
to fetalmouse serum usingthefreefractionof
estradiol as a reference (Tables 2,3); we pre-
dicted that bisphenol A would be over 500-
fold more estrogenic than octylphenol in the
mouse fetus. These two xenoestrogens were
chosen for further studybecause theyshowed
the greatest change in access to estrogen
receptors in MCF-7 cells (the largest and
smallest SMA values) between serum-free
medium andserum.
For our in vivo bioassay, we focused on
the potential for bisphenol A and octylphe-
nol to exert estrogenic effects in the mouse
fetus based on prior information on the
potency ofestradiol in fetal mice from stud-
ies of the intrauterine position (IUP) phe-
nomenon. We have shown that a small
increase in serum estradiol during fetal life
was related to enlargement ofthe prostate in
adulthood. Specifically, a 23-pg/ml (23 parts
pertrillion, ppt) increase in total serum estra-
diol in male mouse fetuses positioned in
utero between two female fetuses (2F males;
101 pg estradiol/ml serum) relative to males
between two male fetuses (2M males; 78 pg
estradiol/ml serum) (35) was associated with
a 20% increase in prostate weight in 2F
males relative to 2M males in adulthood
(16). Subsequently, we experimentally veri-
fied these findings in mice by implanting
Silastic capsules (Dow Chemical, Midland,
IN) containing estradiol into pregnant mice
to produce a very small increase in total
serum estradiol during reproductive tract
organogenesis in male fetuses, which led to a
25-30% increase in prostate weight in treat-
edmaleswhentheywere adults (17).
These observations and the results ofthe
RBA-SMA assay were used to calculate the
circulating concentration or reference dose in
pregnant mice that we expected to produce
an increase in prostate weight in male off-
spring. Calculation of reference dose was
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based on the IUP studies inwhich an increase
in total serum estradiol of23 pg/ml resulted
in permanent prostate enlargement in 2F
male mice relative to 2M male mice and on
the predicted bioactivity ofbisphenol A rela-
tive to estradiol in fetal mice from Table 3
(0.09%). With these two pieces ofinforma-
tion, reference doses of bisphenol A and
octylphenol were calculated that would be
equivalent to an increase in serum estradiol in
male fetuses of23 pg/mI andwould thus pro-
duce prostate enlargement. For comparison,
reference doses were also calculated using the
RBAs that we determined in serum-free
medium; these relative activities are represen-
tative of the values that have been obtained
with assays which do not take the effects of
serum into account when measuring xenoe-
strogen activity (3-5,15).
This calculation (Table 4) predicted that
bisphenol A at 21 pig/kg would lead to an
increase in prostate weight in male mice;
however, since octylphenol was predicted to
be over 500-fold less estrogenic than bisphe-
nol A, neither ofthe two doses we adminis-
tered (2 and 20 pg/kg bw) was predicted to
produce an increase in prostate weight in
males exposed to octylphenol. When bisphe-
nol A was administered by feeding to preg-
nant mice at 20 pg/kg, the approximate ref-
erence dose, there was a significant 35%
increase in prostate weight in male offspring.
In contrast, neither dose of octylphenol
altered prostateweight.
Because the calculation ofreference dose
above does not include the effects ofmetab-
olism and pharmacokinetics and because
bisphenol A also exhibited estrogenic effects
at the lowest dose we administered (2
pg/kg), bisphenol A appeared to be more
estrogenic in vivo than predicted. We (17)
have found that the estrogenic activity of
bisphenol A was only 100-fold lower (or
less) than that of diethylstilbestrol (DES)
when using the prostate as a bioassay, again
indicating that bisphenol A appeared to be
more estrogenic in vivo than predicted.
Several possible mechanisms could explain
this. Arnold et al. (36) reported that some
xenoestrogens act synergistically and have
greater activity in mixtures than predicted
when the individual compounds are assayed
alone. It is possible that bisphenol A acts
synergistically with the phytoestrogens,
including genistein, known to be present in
soy-based mouse chow. Alternatively,
bisphenol A may be bioactivated in vivo to a
more estrogenic metabolite (in addition,
octylphenol may be metabolized to a less
estrogenic compound). Additionally,
bisphenol Amay bind even less to the serum
proteins in fetal mouse serum than to those
in adult human serum, thus having greater
activity and greater SMA in fetal mouse
Table 4. Calculation ofxenoestrogen reference doses
Equivalent
Estradiol Predicted estrogenic
Compound referencea bioactivityb activityc MW, pg/pmol Reference dosed
In serum
Bisphenol A 84 pM 0.09% = 0.093 pM x 228.3 = 21 pg/kg
Octylphenol 84 pM 0.00016% = 52.5 pM x 208.3 = 10,900 pg/kg
In serum-free
Bisphenol A 84 pM 0.006% = 1.400 pM x 228.3 = 320 pg/kg
Octylphenol 84 pM 0.072% = 0.117 pM x 208.3 = 24 pg/kg
aFetal estradiol elevation that resulted in adult prostate enlargement: 84 pM (= 23 pg/ml) (16,35).
bFrom Table 3, activity relative to estradiol, based on relative molar concentrations; the predicted bioac-
tivities SERUM-FREE are the RBAs measured in Serum-Free Medium.
cMolar concentration ofxenoestrogen predictedto equal the estrogenic activity ofthe estradiol reference.
dEquivalent estrogenic activity in mol/liter converted to mass, pg/liter; value then expressed as pg/kg for
reference dose; MW of bisphenol A = 228.3; MW of octylphenol = 208.3.
serum than was predicted by extrapolation
from results obtained in adult human
serum. Finally, a novel estrogen receptor,
termed ER-beta, has recently been cloned
(37). ER-beta is expressed in the rodent
prostate (37), and this estrogen receptor
may have a different responsiveness for
bisphenol A than does the classical ER-alpha
present in MCF-7 cells.
The RBA-SMA assay accurately predict-
ed the relative bioactivity ofbisphenol A and
octylphenol in the animal by incorporating
the effects of serum, whereas the intrinsic
activity of the xenoestrogens measured in
serum-free assays did not predict in vivo
bioactivity (Table4). The RBA-SMA assay is
thus an improvement on existing in vitro
assays for predicting the bioactivity ofxenoe-
strogens in the animal. However, the indu-
sion of additional information, such as
metabolism and pharmacokinetics ofxenoe-
strogens, would further increase the accuracy
ofin vitroassays aspredictors ofbioactivity.
Xenoestrogens are often referred to as
weak estrogens that are not likely to be bio-
logically active at environmentally relevant
concentrations. In our study, a maternal dose
ofonly 2 /kg/daybisphenol Aenlarged the
prostate in male offspring. This dose is equiv-
alent to a daily dose of 50 pg for a 25-kg
child or 150 pg for a 75-kg adult. In this
regard, Olea et al. (7) have shown that after a
50-mg dental sealant treatment, the saliva
measured in a 1-hr collection after the appli-
cation of the sealant from human subjects
contained from 90 to 931 pg ofbisphenol A.
They also measured bisphenol A in the saliva
of an individual who had tooth sealant
applied 2 years earlier and found 66.4 pg in a
1-hrsaliva collection before additional sealant
treatment, suggesting that bisphenol A may
be continually released after the initial dental
work. Brotons et al. (6) analyzed vegetables
packaged in food cans with lacquer coating
andfound thatas much as 23 pgofbisphenol
A was recovered from 50 ml of the liquid
portion ofone food can. An important aspect
ofour study is the proximity ofthe maternal
doses of bisphenol A administered to preg-
nant mice and the reported ranges ofhuman
exposure to this chemical.
Although we did not find estrogenic
effects of octylphenol in this animal study,
Sharpe et al. (38) recendy reported effects on
the male reproductive tract in rats that were
exposed to octylphenol administered orally
to their mothers before pregnancy, during
gestation, and throughout lactation. These
effects were seen at doses that mayhave been
at or above our highest dose, although it was
difficult to determine postnatal dose, and
prenatal dose was not determined (38). It is
possible that ifwe administered these com-
pounds throughout pregnancy and lactation,
rather than just 7 days during pregnancy,
there may have been a different outcome
with regard to octylphenol. It is well known
that different effects are seen with prenatal
versus postnatal estrogen exposure in rodents
(35). Also important here are the high levels
ofestrogens during fetal development versus
the very low levels between birth and puber-
ty (27,39), and this may also affect the sensi-
tivity of the developing male reproductive
tract to environmental estrogens.
If a xenoestrogen interacts with serum-
binding proteins in the same manner as
estradiol, then the RBA-SMA assay will not
change the prediction ofits estrogenic activi-
ty relative to estradiol. However, ofthe more
than 12 xenoestrogens that we have tested
thus far, none has shown the same serum-
modified access as estradiol. By incorporat-
ing the effects of serum on xenoestrogens,
the2-dayRBA-SMAassayprovided an accu-
rate prediction ofthe bioactivities ofbisphe-
nol A and octylphenol. This assay should
thus be ofconsiderable interest to toxicolo-
gists seeking to estimate the dose ofa xenoe-
strogen to administer to animals within a
physiological range of estrogenic activity
rather than in the toxicological range used in
traditional high-dose studies oftoxicants. For
systemic toxicants, the mechanism ofaction
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is typically unknown, and a comparison of
administered dose to the concentration ofan
endogenous standard (such as estradiol for
xenoestrogens) cannot be made. In contrast,
for axenoestrogen, the RBA-SMAassaycou-
pled with information about endogenous
concentrations and the developmental effects
ofestrogen can be used to predict bioactive
doses. Our findings, in addition, reveal that
fetal exposure to bisphenol A can alter the
reproductive tract in rodents at much lower
doses than previously thought to be active.
The predicted NOEL (no observed effect
level) for bisphenol A has been estimated at
50 mg/kg bw/day (40); however, bisphenol
A was active in rodents at 2 and 20
fig/kg/day, which lies near or within the
reported ranges of current human exposure
to this chemical (6 7,40).
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